The U.S. Food and Drug Administration approved Priovant's LISRAYA (brepocitinib) as the first targeted therapy for adults with dermatomyositis, a rare autoimmune disease marked by painful skin rashes and muscle weakness. Orsini said it will serve as a specialty pharmacy partner for the once-daily oral treatment. In the VALOR study, described as the largest placebo-controlled dermatomyositis trial conducted, LISRAYA produced clinically meaningful improvements in global myositis response, skin disease, muscle strength, functional disability and steroid sparing. The condition can also involve lung, cardiac and gastrointestinal complications. LISRAYA carries a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis, and is not recommended with other JAK or TYK2 inhibitors or biologic DMARDs. An earlier report said Roivant shares rose nearly 3% to $37.69 and that the disease affects fewer than 5,000 people in the U.S.